KalVista Pharmaceuticals (KALV) Competitors

KalVista Pharmaceuticals (NASDAQ:KALV) and Twist Bioscience (NASDAQ:TWST) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, community ranking, earnings and risk.

Do analysts rate KALV or TWST?

KalVista Pharmaceuticals presently has a consensus target price of $24.83, suggesting a potential upside of 99.46%. Twist Bioscience has a consensus target price of $52.80, suggesting a potential upside of 40.35%. Given KalVista Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe KalVista Pharmaceuticals is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KalVista Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.13
Twist Bioscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Which has more volatility and risk, KALV or TWST?

KalVista Pharmaceuticals has a beta of 0.39, meaning that its share price is 61% less volatile than the S&P 500. Comparatively, Twist Bioscience has a beta of 2.34, meaning that its share price is 134% more volatile than the S&P 500.

Does the MarketBeat Community favor KALV or TWST?

KalVista Pharmaceuticals received 244 more outperform votes than Twist Bioscience when rated by MarketBeat users. Likewise, 75.05% of users gave KalVista Pharmaceuticals an outperform vote while only 58.99% of users gave Twist Bioscience an outperform vote.

Company	Underperform	Outperform
KalVista Pharmaceuticals	Outperform Votes 349 75.05%	Underperform Votes 116 24.95%
Twist Bioscience	Outperform Votes 105 58.99%	Underperform Votes 73 41.01%

Does the media favor KALV or TWST?

In the previous week, KalVista Pharmaceuticals had 1 more articles in the media than Twist Bioscience. MarketBeat recorded 4 mentions for KalVista Pharmaceuticals and 3 mentions for Twist Bioscience. KalVista Pharmaceuticals' average media sentiment score of 1.44 beat Twist Bioscience's score of 1.18 indicating that KalVista Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
KalVista Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Twist Bioscience	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is KALV or TWST more profitable?

KalVista Pharmaceuticals has a net margin of 0.00% compared to Twist Bioscience's net margin of -59.76%. Twist Bioscience's return on equity of -32.69% beat KalVista Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KalVista Pharmaceuticals	N/A	-103.92%	-88.06%
Twist Bioscience	-59.76%	-32.69%	-25.25%

Which has higher valuation and earnings, KALV or TWST?

KalVista Pharmaceuticals has higher earnings, but lower revenue than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than KalVista Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KalVista Pharmaceuticals	N/A	N/A	-$126.64M	-$3.72	-3.35
Twist Bioscience	$330.19M	6.80	-$208.73M	-$3.38	-11.13

Summary

KalVista Pharmaceuticals beats Twist Bioscience on 10 of the 16 factors compared between the two stocks.